Evidence map›Paper›PMID 40478199›Full record

ArticleLiver international : official journal of the International Association for the Study of the Liver2025

Deep Learning Reveals Liver MRI Features Associated With PNPLA3 I148M in Steatotic Liver Disease.

Yazhou Chen, Benjamin P M Laevens, Teresa Lemainque, Gustav Anton Müller-Franzes, Tobias Seibel, Carola Dlugosch, Jan Clusmann, Paul-Henry Koop, Rongpeng Gong, Yuanyuan Liu and 17 more

Abstract read
In one paragraph

Article in Liver international : official journal of the International Association for the Study of the Liver, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Fifteen Years of PNPLA3: Transforming Hepatology Through Human Genetics.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Yazhou ChenDepartment of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.ORCID 0009-0005-9893-645X
Benjamin P M LaevensDepartment of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.
Teresa LemainqueDepartment of Diagnostic and Interventional Radiology, University Hospital RWTH Aachen, Aachen, Germany.
Gustav Anton Müller-FranzesDepartment of Diagnostic and Interventional Radiology, University Hospital RWTH Aachen, Aachen, Germany.
Tobias SeibelDepartment of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.ORCID 0009-0004-9115-3228
Carola DlugoschDepartment of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.
Jan ClusmannDepartment of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.
Paul-Henry KoopDepartment of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.
Rongpeng GongDepartment of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.
Yuanyuan LiuDepartment of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.
Niharika JakharDepartment of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.
Feng CaoDepartment of General Visceral and Transplantation Surgery, University Hospital RWTH Aachen, Aachen, Germany.
Simon SchophausDepartment of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.ORCID 0009-0004-4767-9775
Thriveni Basavanapura RajuDepartment of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.
Anastasia Artemis RaptisDepartment of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.
Felix van HaagDepartment of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.ORCID 0009-0007-4586-7133
Joel JoyDepartment of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.ORCID 0009-0002-9926-6070
Rohit LoombaMASLD Research Center, Division of Gastroenterology and Hepatology, Department of Medicine, University of California, San Diego, California, USA.
Luca ValentiDepartment of Pathophysiology and Transplantation, University of Milan, Milan, Italy.ORCID 0000-0001-8909-0345
Jakob Nikolas KatherElse Kroener Fresenius Center for Digital Health, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
Titus J BrinkerDigital Biomarkers for Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Moritz HerzogElse Kroener Fresenius Center for Digital Health, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
Ivan G CostaInstitute for Computational Genomics, RWTH Aachen, Aachen, Germany.
Diego HernandoDepartment of Radiology, University of Wisconsin, Madison, Wisconsin, USA.
Kai Markus SchneiderDepartment of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.
Daniel TruhnDepartment of Diagnostic and Interventional Radiology, University Hospital RWTH Aachen, Aachen, Germany.
Carolin V SchneiderDepartment of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.ORCID 0000-0002-6728-9246

Funding

UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
Pediatric Trials in Non-Alcoholic Steatohepatitis (NASH)U01DK061734 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ROHIT LOOMBA · 2002 to 2026
$24.4M
Tissue-specific roles of FXR in CVD and NASHP01HL147835 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LOOMBA, ROHIT · 2020 to 2024
$12.2M
San Diego Digestive Diseases Research CenterP30DK120515 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Bernd G. Schnabl · 2019 to 2026
$10.8M
HIV MASLD Clinical Research Network (HCRN)R01DK121378 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI NAGA P CHALASANI, ROHIT LOOMBA · 2020 to 2026
$8.7M
Integration of epidemiology, pathology, immunology and outcomes in colorectal cancerR01CA263318 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI STEPHEN B GRUBER · 2022 to 2026
$3.4M
QUS Technology for Diagnosis and Grading of Hepatic Steatosis in NAFLDR01DK106419 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LOOMBA, ROHIT, SIRLIN, CLAUDE B · 2015 to 2019
$3.4M
San Diego Cirrhosis Clinical Research NetworkU01DK130190 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ROHIT LOOMBA · 2021 to 2026
$2.3M
Non-invasive screening of diabetics for advanced fibrosis due to NAFLDR01DK124318 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LOOMBA, ROHIT · 2020 to 2022
$1.7M
Deutsche ForschungsgemeinschaftNCATS NIH HHS UL1 TR001442NCI NIH HHS R01 CA263318NHLBI NIH HHS P01 HL147835NIDDK NIH HHS P30 DK120515NIDDK NIH HHS R01 DK106419NIDDK NIH HHS R01 DK121378NIDDK NIH HHS R01 DK124318NIDDK NIH HHS U01 DK061734NIDDK NIH HHS U01 DK130190
6 · The paper itself

Abstract

backgroundSteatotic liver disease (SLD) is the most common liver disease worldwide, affecting 30% of the global population. It is strongly associated with the interplay of genetic and lifestyle-related risk factors. The genetic variant accounting for the largest fraction of SLD heritability is PNPLA3 I148M, which is carried by 23% of the western population and increases the risk of SLD two to three-fold. However, identification of variant carriers is not part of routine clinical care and prevents patients from receiving personalised care.

methodsWe analysed MRI images and common genetic variants in PNPLA3, TM6SF2, MTARC1, HSD17B13 and GCKR from a cohort of 45 603 individuals from the UK Biobank. Proton density fat fraction (PDFF) maps were generated using a water-fat separation toolbox, applied to the magnitude and phase MRI data. The liver region was segmented using a U-Net model trained on 600 manually segmented ground truth images. The resulting liver masks and PDFF maps were subsequently used to calculate liver PDFF values. Individuals with (PDFF ≥ 5%) and without SLD (PDFF < 5%) were selected as the study cohort and used to train and test a Vision Transformer classification model with five-fold cross validation. We aimed to differentiate individuals who are homozygous for the PNPLA3 I148M variant from non-carriers, as evaluated by the area under the receiver operating characteristic curve (AUROC). To ensure a clear genetic contrast, all heterozygous individuals were excluded. To interpret our model, we generated attention maps that highlight the regions that are most predictive of the outcomes.

resultsHomozygosity for the PNPLA3 I148M variant demonstrated the best predictive performance among five variants with AUROC of 0.68 (95% CI: 0.64-0.73) in SLD patients and 0.57 (95% CI: 0.52-0.61) in non-SLD patients. The AUROCs for the other SNPs ranged from 0.54 to 0.57 in SLD patients and from 0.52 to 0.54 in non-SLD patients. The predictive performance was generally higher in SLD patients compared to non-SLD patients. Attention maps for PNPLA3 I148M carriers showed that fat deposition in regions adjacent to the hepatic vessels, near the liver hilum, plays an important role in predicting the presence of the I148M variant.

conclusionOur study marks novel progress in the non-invasive detection of homozygosity for PNPLA3 I148M through the application of deep learning models on MRI images. Our findings suggest that PNPLA3 I148M might affect the liver fat distribution and could be used to predict the presence of PNPLA3 variants in patients with fatty liver. The findings of this research have the potential to be integrated into standard clinical practice, particularly when combined with clinical and biochemical data from other modalities to increase accuracy, enabling easier identification of at-risk individuals and facilitating the development of tailored interventions for PNPLA3 I148M-associated liver disease.

Indexed as

Deep LearningFatty LiverLipaseLiverMagnetic Resonance ImagingMembrane ProteinsNon-alcoholic Fatty Liver DiseaseAcyltransferasesAdultAgedFemaleGenetic Predisposition to DiseaseHumansMaleMiddle AgedPhospholipases A2, Calcium-IndependentAcyltransferasesLipaseMembrane ProteinsPhospholipases A2, Calcium-IndependentPNPLA3 protein, humandeep learningmedical imaging processsingle nucleotide polymorphismsteatotic liver disease

Identifiers

PMID40478199
PMCPMC12143367

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.